Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Feds hold groundbreaking ceremony for Moderna's mRNA vaccine factory in Montreal area
https://montreal.ctvnews.ca/feds-hold-groundbreaking-ceremony-for-moderna-s-mrna-vaccine-factory-in-montreal-area-1.6142301
I want to see who the winner is ;> Patent wars: Moderna’s battle for the spoils of Covid vaccines
Ending of pharma group’s IP truce spells fight for future of mRNA technology
https://www.ft.com/content/5769f077-641e-4d37-adc6-7634c59b6d5d?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev
A combination vaccine for flu and COVID-19 is in the works. Here's what to know.
huge news: Human trials are underway to assess the safety and efficacy of a flu-COVID combination vaccine.
Moderna has finished enrolling trial participants while Pfizer-BioNTech isn't too far behind.
Health experts say these combination vaccines could be available as early as next flu season.
https://eu.usatoday.com/story/news/health/2022/11/07/flu-covid-vaccine-pfizer-moderna/8257444001/
REV 3.4B, EPS 2.53
-2022 est 18 - 19B$
-Pipeline 48 programs, 45 categories, 35 are in clinical trials
-PVC PII data expected 4Q22
-RSV PIII data expected this winter
-FLU PIII data 1Q23
Cash/cash equivalent at end of 3Q, 17B$
How money was spent
-Repurchase 24M share for 2.9B$ (complete) reduces outstanding shares (405M to 387M)
-Started a 2d buyback plan (3B$) as announced in AUG22
-Reinvested 820M$ in R&D (pipeline)
-Losses, 333M$ write off on CV19 product, and 102M$ from canceled purchase agreements
$MRNA multibaggers
Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations
https://www.nature.com/articles/s41564-022-01269-8
November and December news in release!!!! Oral Presentation Title: First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
CAN-2409 is also being evaluated in multiple phase 2 and phase 3 clinical trials for lung, brain, pancreatic, and prostate cancers.
but we will have more new data and a new cohort of 11 patients in December this year."
https://www.healthleadersmedia.com/pharma/just-two-years-helm-ceo-paul-peter-tak-transforms-candel-and-cancer-treatment
The U.S. is officially in a flu epidemic, federal health officials say. They’re preparing to deploy troops and ventilators if necessary
https://fortune.com/well/2022/11/04/us-united-states-in-flu-epidemic-federal-health-officials-say-cdc-hhs-rsv-covid-omicron-2022/
2023 Advanced Purchase Agreements
BIG COMPANY,,,,,,,,,
Confirmed APAs, as well as previously deferred product sales, currently represent $4.5-$5.5 billion in anticipated product sales in 2023. The Company expects additional sales in key markets, including the U.S., E.U., Japan, Middle East, Latin America and Asia Pacific in 2023.
From the end of the third quarter of 2021 to the end of the third quarter of 2022, the Company repurchased 24 million shares, reducing the number of common shares outstanding from 405 million to 387 million, more than offsetting 5 million shares of common stock issued in connection with equity compensation over this period.
CMV vaccine (mRNA-1647) pivotal Phase 3 study, known as CMVictory, is ongoing.
$MRNA
The good news is that RSV vaccines are on the way:
Moderna Inc. says its vaccine for respiratory syncytial virus, better known as RSV, could be ready for commercialization as soon as next year.
The Cambridge drugmaker is currently running a Phase 3 trial of its mRNA-based RSV vaccine. Data is expected sometime this winter; if it meets expectations, then Moderna could launch it before the fall 2023 sick season, executives said on the company's third-quarter earnings call Thursday morning.
$MRNA
U.S. faces highest flu hospitalization rate in a decade with young kids and seniors most at risk
Cases of respiratory syncytial virus, or RSV, is also increasing in almost every region of the U.S.
$MRNA Phase 3 RSV vaccine efficacy data could read out this winter
Phase 3 flu vaccine immunogenicity data expected in 1Q23
https://www.cnbc.com/2022/11/04/us-faces-highest-flu-hospitalization-rate-in-a-decade.html
Beth, I'm not reporting on this any more. Should I be worried about this? $MRNA
GREEN DAY LOL...... MRNA WINNER$$$$$$$$
Reflecting on More Than a Decade of Progress on mRNA Science:
read about the development of our mRNA platform and pipeline which includes 47 programs in development, including 31 in clinical studies.
https://endpts.com/sp/reflecting-on-more-than-a-decade-of-progress-on-mrna-science/
ER is good: Approximately $61 Million of International Sales in the Third Quarter –
As of September 30, 2022, we had $109.7 million in cash and cash equivalents compared with $103.1 million at December 31, 2021.
As of September 30, 2022, we had outstanding purchase orders associated with manufacturing obligations in the aggregate amount of approximately $21.8 million.
https://investor.siga.com/news-releases/news-release-details/siga-reports-financial-results-three-and-nine-months-ended-0
Biden Admin Renews Public Health Emergency Over Monkeypox
https://www.zerohedge.com/medical/biden-admin-renews-public-health-emergency-over-monkeypox
impatient mannequins$$$$$$$$
money machine moderna!!!! green
Primary efficacy analysis from Phase 2 study for personalized cancer vaccine program (mRNA-4157/V940) expected in 4Q22
Phase 3 RSV vaccine efficacy data could read out this winter
Phase 3 flu vaccine immunogenicity data expected in 1Q23
BIG NEWS IMMINENT$$$$$$$$$$
Cash Position: Cash, cash equivalents and investments as of September 30, 2022 and December 31, 2021 were $17.0 billion and $17.6 billion, respectively.
2023 Advanced Purchase Agreements
Confirmed APAs, as well as previously deferred product sales, currently represent $4.5-$5.5 billion in anticipated product sales in 2023. The Company expects additional sales in key markets, including the U.S., E.U., Japan, Middle East, Latin America and Asia Pacific in 2023.
Share Repurchase Program
The $3 billion share repurchase program announced in February 2022 was completed early in the fourth quarter 2022. The Company has commenced repurchases from the additional $3 billion program announced in August 2022.
Moderna now has 48 programs in development across 45 development candidates[1], of which 35 are currently in active clinical trials. The Company's updated pipeline can be found at www.modernatx.com/pipeline. Moderna and collaborators have published more than 130 peer reviewed manuscripts.
Cash Used for Repurchases of Common Stock: Cash used for repurchases of common stock was $2.9 billion for the nine months ended September 30, 2022. Moderna did not conduct share repurchases prior to the fourth quarter of 2021. From the end of the third quarter of 2021 to the end of the third quarter of 2022, the Company repurchased 24 million shares, reducing the number of common shares outstanding from 405 million to 387 million, more than offsetting 5 million shares of common stock issued in connection with equity compensation over this period.
now or never$$$$$$$$
Third quarter 2022 revenues of $3.4 billion; GAAP net income of $1.0 billion and GAAP diluted EPS of $2.53
https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Business-Updates/default.aspx
There is a new video just out today on youtube featuring Bob Langer expressing his hopes and perspective on Moderna's personal cancer vaccine. The video: "Breaking down biotech innovation with Dr. Bob Langer."
WHO declares monkeypox still a global health emergency
WHO kept monkeypox on its highest alert level
https://www.foxnews.com/health/who-declares-monkeypox-still-global-health-emergency
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
Moderna, Inc.
Tue, November 1, 2022 at 6:30 AM
all over the world pay for the war!
This is the evil of the economy
when it ends,Things will change soon....
In the span of just seven trading sessions, there will be four major events that could shape the market’s outlook for the rest of the year -- and potentially prompt a rapid about-face by confounding expectations.
On Nov. 2, the Federal Reserve will announce its latest interest-rate decision and give hints about its path forward, possibly signaling plans to ease back from the aggressive pace of hikes that’s threatening to drive the economy into a recession.
Two days later, the October jobs report will provide an important look at how much hiring is slowing. Then on Nov. 8, the mid-term elections may usher in a change in which party controls Congress. And finally, on Nov. 10 there’s the consumer price index, a report that’s played a key role in shaping expectations for the Fed’s path since inflation roared back to a four-decade high.
let's see what will happen........
On Tuesday, Morgan Stanley analyst Matthew Harrison provided an encouraging view of Moderna's upcoming analysis of a phase 2 study for its personalized cancer vaccine as an adjuvant treatment for patients with high-risk melanoma. Harrison believes Merck's recent decision to exercise its option to jointly develop and commercialize the drug suggests the results will be positive.
RELAX$$$$$$$
Moderna will join Pfizer an announce $100+ shot after government buy ends. They don't need to see 300million any more just 50 million will generate 5 Billion a year!!!!!!!!!
Plus next year they roll out the flu shot for an even bigger market.
RELAX!!!!!!
Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer
Furthermore, more than 700 patients have been dosed to date with a favorable safety profile, supporting the potential for combination with other therapeutic strategies without inordinate concern of overlapping adverse events. Currently, Candel is evaluating the effects of treatment with CAN-2409 in high-grade glioma, non-small cell lung cancer, pancreatic cancer, and prostate cancer in ongoing clinical trials.
Analysts Estimate Moderna to Report a Decline in Earnings!!!!!!!
This biotechnology company is expected to post quarterly earnings of $3.02 per share in its upcoming report, which represents a year-over-year change of -60.8%.
Revenues are expected to be $3.33 billion, down 33% from the year-ago quarter.
"let's see what will happen"
MERCK beats estimates. Article talks about collaboration with MRNA on cancer treatment.
The new vaccine, Moderna said, is undergoing mid-stage trials with data expected before the end of the year.
https://www.thestreet.com/markets/merck-stock-jumps-keytruda-drives-q3-profit-beat-forecast-boost?puc=yahoo&cm_ven=YAHOO
NOVEMBER 3, 2022 08:00 AM ET
Moderna 3Q 2022 Earnings Call
NOVEMBER 10, 2022 09:00 AM ET
Moderna ESG Day 2022
https://finance.yahoo.com/news/moderna-host-first-environmental-social-200500069.html
Moderna Named a Top Employer by Science for Eighth Consecutive Year
https://finance.yahoo.com/news/moderna-named-top-employer-science-185000411.html
this is very interesting: https://www.healthleadersmedia.com/pharma/just-two-years-helm-ceo-paul-peter-tak-transforms-candel-and-cancer-treatment
CAN-2409 is also being evaluated in multiple phase 2 and phase 3 clinical trials for lung, brain, pancreatic, and prostate cancers.
but we will have more new data and a new cohort of 11 patients in December this year."
Key Upcoming Milestones big news imminent$$$$$$$$......
In the fourth quarter of 2022, the Company expects to present new data from three clinical trials:
A phase 1b clinical trial of CAN-2409 in combination with nivolumab (Opdivo®) combined with standard of care in first line treatment in patients with high-grade glioma.
A phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma.
A phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 or PD-L1 agents in patients with stage III/IV NSCLC.
The Company anticipates initiating a phase 3 clinical trial evaluating CAN-2409 in patients with high-grade glioma in the third quarter of 2022.
Moderna close to U.S. deal to make vaccines for Ebola, biological threats
https://finance.yahoo.com/news/1-moderna-close-u-deal-170128224.html
relax$$$$$$$$
The largest iPhone factory in the world, owned by the Foxconn Technology Group in the central Chinese city Zhengzhou, has been hit by a Covid-19 outbreak, the South China Morning Post reported.
the covid does not exist .....LOL
https://www.scmp.com/tech/tech-trends/article/3197287/foxconns-largest-iphone-factory-confirms-covid-19-impact-after-central-china-campus-restricted
What the Smartest Investors Know About Moderna Stock
Future prospects go far beyond COVID-19
It's written on the wall over here!!!!!!!
relax$$$$$$$$$
https://www.fool.com/investing/2022/10/18/what-smartest-investors-know-about-moderna-stock/
November 8, 2022 LOL end of the world......
New Covid wave expected in coming weeks, EMA official warns
“The pandemic is not over yet,”
https://www.ekathimerini.com/news/1196541/new-covid-wave-expected-in-coming-weeks-ema-head-warns/
One can see Moderna’s US updated booster is taking better then half the marketshare and that was with availability issues.
https://www.statista.com/statistics/1198516/covid-19-vaccinations-administered-us-by-company/
Could This News from Pfizer Equal Billions for Moderna $$$$$$$$$$
But in the not-too-distant future, coronavirus vaccines will enter the private market. This means vaccine makers will sell vaccines directly to distributors to be administered in pharmacies and other healthcare settings.
The big pharma player last week said it aims to sell its vaccine within the range of $110 to $130 per dose in the U.S. private market next year. This is higher than some Wall Street estimates of about $50 per dose. And it's at least three times higher than the price the U.S. government pays per dose today.
https://www.nasdaq.com/articles/could-this-news-from-pfizer-equal-billions-for-moderna